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orders. We then focus on the mechanistic basis of microbial 
immunomodulation, which is presented using several well-
understood paradigmatic examples, that is, helminths,  Heli-
cobacter pylori , Bifidobacteria and Lactobacilli. In a final 
chapter, we highlight past and ongoing attempts at harness-
ing the immunomodulatory properties of GI microbiota spe-
cies and their secreted products for intervention studies and 
describe the promises and limitations of these experimental 
approaches. The effects of pro- and prebiotics, bacterial ly-
sates, as well as of fecal microbiota transplantation are pre-
sented and compared.  © 2016 S. Karger AG, Basel 
 Observational Studies Support a Critical Role of the 
GI Microbiota in Modifying Allergy Risk 
 Individual allergy risk is known to be influenced by 
environmental and lifestyle factors including diet, coun-
try of birth, exposure to antibiotics – especially early in 
life – sanitation, exposure to pets and livestock, the deliv-
ery mode, and breastfeeding, as well as genetic and epi-
genetic factors. Epidemiological and experimental stud-
ies support the hypothesis that the composition and di-
versity of the gastrointestinal (GI) microbiota heavily 
influences the risk of the development of allergic diseases.
 Modern culture-independent techniques have provid-
ed a comprehensive picture of the gut microbiota, its di-
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 Abstract 
 The gastrointestinal (GI) tract microbiota is required for op-
timal digestion of foods, for the development of resistance 
against pathogens (termed colonization resistance), for the 
development of mucosa-associated lymphoid tissue, and for 
local as well as systemic immune homeostasis. Certain con-
stituents of the GI tract microbiota are widely recognized as 
critical regulators and modulators of their host’s immune re-
sponse. These include bacterial members of the microbiota 
as well as parasitic nematodes. Immune regulation by immu-
nomodulatory members of the GI microbiota primarily 
serves to subvert host antimicrobial immune defenses and 
promote persistent colonization, but as a side effect may 
prevent or suppress immunological disorders resulting from 
inappropriate responses to harmless antigens, such as aller-
gy, colitis or autoimmunity. Many of the best understood GI-
resident immunomodulatory species have co-evolved with 
their mammalian hosts for tens of thousands of years and 
masterfully manipulate host immune responses. In this re-
view, we discuss the epidemiological evidence for the role of 
the GI tract microbiota as a whole, and of specific members, 
in protection against allergic and other immunological dis-
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versity and alterations due to environmental influences 
 [1] . They are based on the amplification and sequencing 
of parts of the 16S rRNA gene  [1, 2] ; alternatively, metage-
nome or metatranscriptome sequencing is applied to ob-
tain a higher resolution overview of the microbiota and 
to allow the detection of archaea, fungi, and viruses in 
addition to bacteria  [1–3] . Other emerging methods are 
metaproteomic and metabolomic analyses, aiming to 
characterize the functionality of the microbiome  [2, 3] . 
Through application of these modern culture-indepen-
dent as well as culture-dependent methods, it has become 
increasingly clear that the composition of the gut micro-
biota is strongly influenced by environmental and life-
style factors, which in turn affect the risk of allergic and 
other non-communicable diseases (NCDs). Better per-
sonal hygiene, smaller family size, dietary changes, and 
the excessive use of antibiotics in industrialized countries 
have all been held responsible for changes in the gut mi-
crobiota and allergy risk  [4–6] . Several studies have re-
ported beneficial effects on allergic outcomes of growing 
up in rural farming environments; livestock exposure, 
and therefore, early or prenatal microbial exposure ap-
pears to account for the lower allergy risk of farmers’ chil-
dren  [7, 8] , which has been attributed mechanistically to 
differences in innate immune responses, as well as in-
creased number and functions of cord blood regulatory T 
cells  [9, 10] . Moreover, bacterial communities in dust 
samples isolated from households with dogs or cats were 
found to be richer and more diverse, and exposure to such 
environments during infancy is known to protect against 
allergic disease development in childhood  [11, 12] .
 A reduced GI tract microbiota diversity is clearly 
linked to early-onset NCDs, including atopy  [13] , eczema 
 [14–17] , and asthma  [18] . The reduced GI microbiota di-
versity in allergic children is dominated by Firmicutes 
 [19–21] , and members of the  Bacteroidaceae family  [22] 
and more specifically, by increased numbers of  Bacteroi-
des fragilis  [23, 24] ,  Escherichia coli  [25] ,  Clostridium dif-
ficile  [17, 25, 26] ,  Bifidobacterium catenulatum  [19–21, 
27] , and  Bifidobacterium longum  [28–30] , and a lower 
prevalence of  Bifidobacterium adolescentis  [28–30] ,  Bifi-
dobacterium bifidum  [28–30] , and  Lactobacillus  species 
 [29–31] . These general trends are not confirmed by all 
studies; for instance, a study in Norway found a lower 
rather than higher concentration of  E. coli among allergic 
individuals  [28] . Also, in a study by Verhulst et al.  [32] , 
children who developed wheezing had a lower prevalence 
of  C. difficile . The reduced exposure of Western popula-
tions to microbes that are not classically categorized as 
constituents of the commensal microbiota, such as the 
gastric colonizer and pathobiont  Helicobacter pylori  [33–
35] , or intestinal helminths  [36, 37] , also increases the risk 
of allergic diseases.
 Lifestyle factors such as delivery mode and breast-feed-
ing strongly affect the establishment of the human gut mi-
crobiota and the risk of allergic outcomes. The recent 
finding that bacterial DNA is present in the newborn’s 
first stool and in the fetoplacental unit suggests that the 
acquisition of the intestinal microbiota may already begin 
in utero and is then further shaped during birth and post-
natally  [38–40] . At birth, first major microbial exposures 
originate from the maternal vaginal and perianal micro-
biota. Consequently, the intestinal microbiota of new-
borns resembles that of his or her mother’s vagina  [41] . In 
contrast, neonates delivered by means of cesarean section 
(CS) acquire a gut microbiota that is similar to the one 
found on maternal skin. This is then followed by the typi-
cally slower (compared to vaginally delivered infants) ac-
quisition of a more complex microbiota  [42, 43] . Infants 
born by means of CS are at higher risk for respiratory dis-
tress  [44] , asthma and atopy  [45] , as well as obesity  [46] , 
and type I diabetes  [47] . Furthermore, CS involves antibi-
otic exposure and can delay the onset of breastfeeding, 
which negatively influence the establishment of a normal 
healthy gut microbiota  [14, 48, 49] . Indeed, breastfed 
(>4 months) neonates exhibited a reduced risk of develop-
ing asthma until 8 years of age  [50] . Evidence is available 
that breastfeeding protects against atopic dermatitis, 
wheeze in early childhood and cow’s milk allergy  [51] . 
However, the data are inconsistent, as other studies have 
reported no benefit of breastfeeding in children from non-
atopic families or in decreasing the risk of asthma in in-
fants at 5 years of age  [52, 53] . Overall, the aforementioned 
studies imply that early-life or even prenatal exposure to 
microbes is critical for shaping a healthy GI tract micro-
biota, which can lower allergy risk later in life.
 Mechanisms of Microbially Induced Immune 
Tolerance and Protection Against Allergic Disorders 
 Intestinal Helminths Protect against Allergy, IBD and 
Autoimmunity by Suppressing Innate Lymphoid Cell 
Activation and Promoting Treg Differentiation 
 Epidemiological and experimental studies have docu-
mented a clear inverse association between helminth in-
fections and allergic, chronic inflammatory and autoim-
mune disease manifestations (reviewed in  [54, 55] ). Para-
sites release immunomodulatory products that have 
evolved to suppress Th2-driven immunity and to ensure 
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helminth persistence, and that, when administered to un-
infected mice, reproduce many of the beneficial effects of 
live infection  [56] . One of the most commonly used mu-
rine models of helminth infection takes advantage of the 
mouse intestinal nematode species  Heligmosomoides 
polygyrus , which can be administered alive in larval form 
and which will colonize virtually all laboratory mouse 
strains, and of its excretory/secretory products ( H. poly-
gyrus excretory/secretory antigen, helminth excretory/se-
cretory (HES)). Experimental  H. polygyrus  infection trig-
gers a Th2-predominant immune response that is accom-
panied by regulatory T-cell expansion and activation in 
the draining mesenteric lymph nodes (MLN)  [57] and 
that typically fails to eliminate the parasites. Live nema-
tode parasite infection of mice, as well as the adoptive 
transfer of MLN-derived Tregs from infected donors to 
uninfected recipients, suppresses allergen-induced air-
way hyper-responsiveness in the recipients and confers 
protection against allergy  [58] ( fig. 1 ). The treatment of 
naive T-cells with HES in conjunction with a TCR ligand 
was shown to trigger the expression of the Treg lineage-
defining transcription factor FoxP3 in vitro through the 
stimulation of TGF-β receptor II signaling, generating 
Tregs with suppressive activity in asthma models  [59] . A 
 Fig. 1. Allergy-preventive mechanisms of intestinal helminths. 
Helminths and other parasitic worms colonize the small intestine 
of humans in tropical and subtropical geographic regions of the 
world. The nematode species  H. polygyrus is used most common-
ly for experimental infections of various susceptible mouse strains. 
Helminths and their HES products locally suppress the activation 
of and cytokine production by type 2 ILCs, and target CD11c lo DC 
subsets to promote their tolerogenic activity. Tregs and Bregs have 
been implicated in suppressing allergen-specific immune respons-
es in the lungs through both IL-10-dependent and -independent 
processes. 
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more recent report on Treg depletion in asthma models 
has, however, challenged the critical role of FoxP3 + Tregs 
in HES-induced asthma protection, instead implicating 
effects on innate lymphoid cells (ILCs) in allergen-specif-
ic immune suppression. This study found that the alum-
adjuvanted sensitization with ovalbumin, which consti-
tutes the first phase of allergen-induced asthma in the 
widely used alum/ovalbumin-induced model of the dis-
ease, triggers the production of IL-5, IL-13 and other cy-
tokines from type 2 ILCs, which is strongly suppressed by 
HES  [60] ( fig. 1 ). Similar findings have been reported in 
an adjuvant-independent model of fungal extract-in-
duced airway hyper-responsiveness  [56] . In addition to 
Tregs and ILCs, dendritic cells (DCs) have been impli-
cated in immunosuppression by both live parasites and 
HES. Treatment with HES inhibits DC-specific cytokine 
production upon TLR activation, as well as other DC 
functions  [61] , a phenomenon that may be recapitulated 
in vivo by the expansion and tolerogenic Treg-inducing 
activity of CD11c lo DCs in the context of  H. polygyrus in-
fection  [62] . In summary, many of the critical cellular and 
molecular players driving helminth-specific immuno-
modulation have been identified in the  H. polygyrus 
mouse model; in contrast, comparatively little is known 
about the correlates of allergy protection by parasites in 
humans. Helminth-infected humans are known for their 
general T-cell hyporesponsiveness  [63] , which in experi-
mental studies on helminth (Ascaris, Trichuris)-infected 
children in Indonesia has been attributed to the higher 
suppressive activity of their FoxP3 + Tregs relative to those 
of uninfected children  [64] . Other studies have docu-
mented higher frequencies of FoxP3 + Tregs in  Schistoso-
ma -infected children relative to their uninfected counter-
parts  [65] . An additional, less well understood subset of 
regulatory lymphocytes, that is, regulatory B-cells (Bregs), 
has also been implicated in helminth-induced allergy 
protection in humans  [66] . Adoptive transfer experi-
ments have confirmed the protective activity of Bregs in 
models of allergen-induced asthma  [66] . The CD24 hi 
CD27 + subset of B-cells, through its capacity to secrete 
IL-10, appears to be specifically involved in helminth-
specific immuno-suppression; both the frequency and 
functionality of this subset are reduced in allergic indi-
viduals  [67] .
 The Gastric Pathobiont H. pylori Suppresses Allergic 
Asthma and IBD by Promoting Tolerogenic DC and 
Regulatory T-Cell Responses 
 H. pylori is an ancestral constituent of the gastric mi-
crobiota that has colonized and co-evolved with its hu-
man host for at least 60,000 years  [68] .  H. pylori causes 
histologically evident, but mostly asymptomatic gastritis 
in all carriers, which may progress to more severe gastric 
disorders such as gastric and duodenal ulcers, and gastric 
cancer or B-cell lymphoma (recently reviewed in  [69] ). 
Whether an infected individual will develop a clinically 
overt disease depends on the host genetic predisposition, 
virulence of the infecting strain, and the polarization and 
strength of the host immune response to the infection 
 [70] . While T-cell responses of patients with  H. pylori -
associated diseases, such as duodenal ulcer, are generally 
Th1/Th2-driven, T-cell responses in asymptomatic carri-
ers tend to be Treg-predominant, with high levels of IL-10 
and TGF-β production  [71] . Similarly, children who rare-
ly suffer from  H. pylori -associated diseases despite being 
colonized at high levels, predominantly mount Treg re-
sponses to their strain  [72] . Despite its strict host specific-
ity ( H. pylori has not been isolated from any other mam-
malian species), certain isolates of  H. pylori  can be used 
for experimental infection of mice  [73, 74] . The require-
ments for eliciting histologically evident gastric disease – 
atrophic gastritis, intestinal metaplasia and other preneo-
plastic lesions – are similar in the human and murine 
host, with a specific contribution of the Cag pathogenic-
ity island to premalignant transformation being observed 
in both settings  [73, 75] . Experimental murine infection 
can be used to recapitulate both asymptomatic carriage 
and  H. pylori -associated disease, with the outcome being 
 driven by a single variable, that is, the age at the time of 
first exposure  [73] . While mice infected during adult-
hood develop chronic gastritis and preneoplastic lesions 
over time, mice infected during the neonatal period 
will  mimic the asymptomatic human carrier and be 
 protected against gastric pathology  [73] ( fig. 2 ). The neo-
natal infection model generates immune tolerance to-
wards  H. pylori that is driven by highly suppressive, 
CD4 + CD25 hi FoxP3 + Tregs, which suppress anti- H. pylori 
T-effector cell-mediated immunity  [73] . An interesting 
side effect of neonatally induced immune tolerance is the 
efficient protection of infected mice against allergic asth-
ma, which is evident in ovalbumin/alum- and house dust 
mite-induced asthma models  [76, 77] . Experimental data 
reflect epidemiological studies in human populations, 
which have documented an inverse association of  H. py-
lori  infection with the risk of developing allergic asthma, 
atopic rhinitis and other allergic disease manifestations 
 [78–82] . The inverse association of  H. pylori status and 
allergy risk was particularly striking in children and early-
onset asthmatics, suggesting that young individuals ben-
efit most from harboring  H. pylori  [78, 80, 81] . As in hel-
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minth infections, Tregs appear to be the main cellular 
players driving tolerance to allergens ( fig. 2 ); the deple-
tion of Tregs breaks tolerance and abrogates protection, 
whereas the adoptive transfer of MLN-derived CD25 + 
Tregs is sufficient to protect naive recipients against al-
lergic asthma  [73, 76] . Several  H. pylori factors are critical 
for Treg differentiation in the context of neonatal infec-
tion with the bacteria; in particular, the secreted factors 
γ-glutamyl-transpeptidase (GGT) and the vacuolating 
cytotoxin (VacA) both non-redundantly contribute to 
Treg differentiation, immune tolerance and asthma pro-
tection  [83] ( fig. 2 ). Both are essential persistence factors 
in  H. pylori infection  [83] and expressed in all strains; 
both factors can further be administered in purified form 
to recapitulate all critical features of immune tolerance 
and allergy protection observed with live infection  [84] . 
Treg differentiation upon exposure to VacA + GGT + H. 
pylori  requires DCs, which are actively targeted and ‘to-
lerized’ by  H. pylori via the two secreted factors  [83] . 
 H. pylori -experienced DCs retain a semi-mature pheno-
type, expressing high levels of MHCII, but low or no co-
stimulatory molecules  [83, 85] . Semi-mature DCs are 
tolerogenic, that is, they exhibit a high propensity for 
priming Treg differentiation, but have only a limited abil-
ity to prime effector T-cell responses  [86, 87] . The tolero-
genic DC/Treg axis likely accounts for the protection of 
 Fig. 2. The gastric pathobiont  H. pylori is typically acquired during 
early childhood, and is known to cause gastric disorders, as well as 
prevent allergic and chronic inflammatory diseases.  H. pylori colo-
nizes the gastric mucosa of roughly one half of the human popula-
tion. Ten to 20% of infected individuals will develop clinically 
overt disease (such as chronic gastritis and gastric ulcers, shown in 
the upper left inset) that is driven by pathogenic T-cells. Greater 
than 80% of the infected population will remain asymptomatic 
throughout life despite harboring high levels of  H. pylori (lower left 
inset). Both outcomes can be recapitulated in experimentally in-
fected mice. The  H. pylori persistence factors GGT and VacA pro-
mote chronic infection by tolerizing DCs and thereby promoting 
Treg differentiation.  H. pylori -induced Tregs are required for the 
suppression of allergen-specific immune responses in the lung and 
for the alleviation of colitis symptoms in models of inflammatory 
bowel disease (upper and lower right insets). Treg- and DC-de-
rived IL-10 contributes to  H. pylori -specific immunomodulation. 
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 H. pylori -infected individuals not only against allergic 
diseases but also against IBD  [88–91] ( fig. 2 ) and poten-
tially against auto-immunity, as demonstrated in models 
of multiple sclerosis  [92] . Overall, much can be learned 
about general microbial immune modulation by studying 
 H. pylori due to readily available experimental infection 
models and the ease of genetic manipulation of these 
highly persistent colonizers of the human stomach.
 Immunomodulatory Lactobacilli and Bifidobacteria 
Induce IL-10 and Retinoic Acid Expression in DCs 
and Promote Treg Differentiation 
 Given the large amount of interventional trials using 
various strains of Lactobacilli and Bifidobacteria (see 
chapter below), it is astonishing how little experimental 
information is available regarding the mechanistic basis 
underlying the protective effects of these classes of mi-
crobes on allergic and other immunologically driven dis-
eases. However, a few concepts have emerged that apply 
to more than one strain and have been tested in rigorous 
experimental systems. One such model system utilizes 
 Bifidobacterium infantis , a strain that was originally iso-
lated from surgically removed, human intestinal mucosa 
and was shown to adhere closely to epithelial cells without 
inducing NF-κB activation and secretion of cytokines and 
chemokines  [93] . Moreover,  B. infantis co-culture not 
only fails to induce, but actively suppresses the release of 
pro-inflammatory molecules by epithelial cells exposed 
to live  Salmonella spp. or purified TLR ligands; similar 
effects are observed with another immunomodulatory 
organism,  Lactobacillus salivarius  [93, 94] . A second, 
non-epithelial target cell of  B. infantis is the antigen-pre-
senting cell, especially the DC. Upon sampling antigenic 
material at sites of pathogen entry, such as the GI mucosa, 
immature sentinel DCs undergo maturation and migrate 
to the tissue-draining lymphoid organs, where they pres-
ent pathogen-specific and co-stimulatory molecules 
(MHC peptide complexes and B7 family molecules) to 
naive T-helper cells. A third, soluble signal provided by 
the DC to the naive T-cells during antigen presentation 
determines the polarization of the T-cell into Th1, Th2, 
Th17 or Treg lineages; the nature of the third signal is 
governed by the conditions encountered by the DCs dur-
ing antigen sampling. Interestingly, DCs directly cultured 
or derived from various human sources (MLN, blood) all 
consistently secrete IL-10, TGF-β and retinoic acid, but 
not IL-12 or TNF-α, upon co-culture with B. infantis  [95, 
96] . IL-10, TGF-β and retinoic acid all contribute to the 
differentiation of naive T-cells into Tregs rather than Th1 
or other T-effector cells, a well-documented consequence 
of  B. infantis  administration to mice  [96] . The CD103 + 
DC subset in the intestinal lamina propria is especially 
equipped to produce retinoic acid and promote Treg dif-
ferentiation; high numbers of intestinal Tregs in turn 
drive the protection against colitis  [96] and allergy that 
is  a hallmark of Bifidobacteria ( B. infantis  and other 
strains) feeding to mice  [97] . Administration of  B. infan-
tis to human volunteers induced increased frequencies of 
FoxP3 + Tregs in peripheral blood  [95] , lending further 
support to the notion that probiotic  Bifidobacterium and 
 Lactobacillus species alleviate allergic and chronic in-
flammatory diseases via the DC/IL-10/retinoic acid/Treg 
axis.
 Interventional Trials Confirm Beneficial Effects of 
Probiotics on Allergic Disease Risk and Severity 
 In the past decades, a range of microbiota-derived 
products has been tested in human clinical trials of aller-
gic and other immunological diseases. The applications 
can be divided into prebiotics, probiotics, bacterial lysates 
(BLs) and fecal microbiota transplantation (FMT). A ma-
jority of intervention studies have examined probiotic 
bacteria. Most studies monitor early outcomes of allergic 
diseases such as eczema and IgE-mediated food allergy, 
whereas only a few studies examine longer-term out-
comes such as respiratory allergic disease.
 Probiotics are live microorganisms which, when ad-
ministered in adequate amounts, confer a health benefit 
to the host  [98] . The first medical application of live bac-
teria was  E. coli Nissle 1917, which was isolated from a 
soldier who survived an epidemic of diarrhea during 
World War 1  [99] . The potential of live microorganisms 
was thereafter neglected for a long time in favor of phar-
maceutical interventions. Most recent studies have been 
conducted using strains of Lactobacilli and Bifidobacte-
ria, and they tend to show benefits in allergy prevention 
but not in the treatment of established allergies  [38] . Sev-
eral very recent trials published in 2013–2015, however, 
have raised new hopes that a reduction of symptoms in 
adult and pediatric allergic rhinitis, eczema and food al-
lergy can be achieved by the use of probiotics ( table 1 ). 
Systematic reviews and meta-analyses suggest that com-
bined pre- and postnatal probiotic supplementation is 
most efficacious in preventing the development of infant 
eczema and atopic eczema  [100–103] , but no convincing 
data on beneficial effects on later-onset allergic diseases 
such as wheezing, allergic asthma or other allergic out-
comes have been reported to date  [104–107] . The lack of 
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efficacy in other allergic disorders may be attributable to 
the time point of treatment onset, which is often late in 
the last trimester of pregnancy or post-natally  [108] ( ta-
ble 1 ). Initiating interventions as early as the beginning of 
the second trimester has been found to increase efficacy 
 [109] . Unconventional probiotics like  Faecalibacterium 
prausnitzii ,  Akkermansia muciniphila , certain  Clostridia 
or  Bacteroides species may prove to be more promising 
than the predominantly used strains of Lactobacilli and 
Bifidobacteria in preventing allergic diseases  [110] . The 
use of helminths has been propagated to treat allergies 
and inflammatory diseases, given the promising results 
from preclinical trials. However, helminths did not con-
fer beneficial effects in allergic asthma patients, and out-
comes for other atopic disorders in humans have been 
inconsistent  [111] .
 BLs, that is, extracts from defined bacterial cultures, 
have originally been developed to prevent recurrent acute 
respiratory tract infections (ARTIs), including the com-
mon cold  [112] . ARTIs are reported to exacerbate asthma 
and wheezing in childhood and to increase the risk of al-
lergies later in life  [113] . The best understood BL, OM-85 
BV (also known as Bronchovaxom) consists of extracts of 
a mixture of bacterial pathogens causing respiratory tract 
infections  [112] . Human clinical studies have revealed 
beneficial effects of OM-85 BV on the recurrence of 
 ARTIs and a reduction of associated symptoms  [113–
116] . Moreover, other BLs have been shown to reduce the 
recurrence and duration of ARTIs  [117, 118] as well as a 
reduction of atopic dermatitis in infants at heredity risk 
for atopy  [119] ( table 1 ).
 Motivated by promising experimental data in mice, 
several clinical trials have assessed the allergy-preventive 
effects of various non-digestible, fermentable oligosac-
charides that are summarized under the term prebiotics. 
These diverse fibers promote the growth of endogenous 
gut bacterial species such as Bifidobacteria and Lactoba-
cilli and thereby enhance microbial metabolic processes 
producing short chain fatty acids (SCFAs) with anti-in-
flammatory properties  [120, 121] . A meta-analysis and 
systematic review of several studies found a significant 
reduction of eczema in infants and a reduction in asthma 
in infants at high risk of allergy upon prebiotic supple-
mentation  [122] . Recently, two trials could show de-
creased allergic food reactivity in young children after 
postnatal prebiotic application as well as alleviated clini-
cal signs in infants with atopic dermatitis (see  table 1 for 
most recent trials). However, due to the shortage of avail-
able data, the benefits of prebiotics on outcomes other 
than eczema remain to be examined  [122, 123] .
 FMT has attracted increased attention lately due to 
its great efficacy in the treatment of  C. difficile -induced 
diarrhea. Several FMT trials for the treatment of IBD 
have recently been evaluated in a systematic review and 
meta-analysis. Overall, the remission rate was signifi-
cantly increased, mainly for Crohn’s disease (60.5%) 
and younger patients (7–20 years, 64.1%) and less con-
vincingly for ulcerative colitis with a remission rate of 
only 22%  [124, 125] . Moreover, FMT is currently being 
investigated as a therapy for pediatric allergic disorders 
 [125] .
 Conclusions and Future Perspectives 
 Observational, experimental and interventional stud-
ies all point to a critical role of a healthy and diverse GI 
tract microbiota in directing tolerance to harmless envi-
ronmental or auto-antigens. Although experimental re-
search and human trials have mostly focused on Lactoba-
cilli and Bifidobacteria in the past, other, less well under-
stood members of the microbiota may turn out to have 
stronger immunomodulatory effects and exhibit better 
efficacy in the prevention and treatment of allergic disor-
ders. Among these are the gastric pathobiont  H. pylori 
 and intestinal helminths; both are persistent colonizers of 
their respective niche and share the ability to induce 
tolerogenic activity in DCs and Treg differentiation in na-
ive T-cells. Longer interventional trials are needed to es-
tablish efficacy beyond atopic eczema in children, and to 
assess possible beneficial effects of pre- and postnatal 
treatment strategies on the allergy risk of adolescents and 
adults. The epigenetic basis for the intergenerational 
transmission of microbial immunomodulatory effects 
will receive increasing attention, and, in combination 
with global microbiome analyses at the genomic, tran-
scriptomic and proteomic levels, will lead to a better un-
derstanding of the regulation of tolerance vs. allergy by 
the constituents of a healthy GI tract microbiota.
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